Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is an innovative Germany-based biotechnology company with a robust oncology pipeline and a first commercialized product, the Pfizer-partnered covid vaccine, Comirnaty. Multiple positive results from Phase 2 trials of pumitamig and gotistobart at the European Lung Cancer Congress (ELCC) 2026 derisk the ongoing and pivotal Phase 3 trials for these drugs and increase confidence in their potential success. Additionally, upcoming updates on the FixVac and BNT122 vaccines in the pipeline could drive further value for shareholders.

Bears say

BioNTech is currently in the early stages of clinical development for its cancer therapeutics and vaccines, and its main commercial product, Comirnaty, is developed in partnership with Pfizer, reducing its potential for revenue growth. The company's financials have also shown a decline in operating cash flow and an increase in debt, further raising concerns about its ability to fund its pipeline and maintain profitability. In addition, competition in the oncology space is rapidly growing, and BioNTech's pipeline is still small and unproven compared to its competitors, with a lack of significant data and a smaller sample size.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $131.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $131.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.